Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. (QLGN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
qlgn · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Qualigen Therapeutics, Inc. (QLGN) measures how much investors pay for each dollar of the company's trailing earnings. QLGN's current PE ratio of N/A is calculated by dividing its stock price of $3.21 by its TTM earnings per share of -$2.65.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Qualigen Therapeutics, Inc.You QLGN | $5M | N/A | — | -$2.65 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
 Clearmind Medicine Inc. CMND | $4M | N/A | — | -$3.03 |
 CNS Pharmaceuticals, Inc. CNSP | $3M | N/A | — | -$35.75 |
 Ensysce Biosciences, Inc. ENSC | $2M | N/A | — | -$3.98 |
 KALA BIO, Inc. KALA | $50M | N/A | — | -$3.31 |
 Kazia Therapeutics Limited KZIA | $18M | N/A | — | -$18.90 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-8.11 | — | |
2024-12-31 FY2024 | — | $-17.03 | — | |
2023-12-31 FY2023 | — | $-2.65 | — | |
2022-12-31 FY2022 | — | $-5.48 | — | |
2021-12-31 FY2021 | — | $-6.10 | — | |
2020-12-31 FY2020 | — | $-7.98 | — | |
2019-12-31 FY2019 | — | $-2.85 | — | |
2018-12-31 FY2018 | — | $-2.26 | — | |
2017-12-31 FY2017 | — | $-14.04 | — | |
2016-12-31 FY2016 | — | $-20.44 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Qualigen Therapeutics, Inc. (QLGN) measures how much investors pay for each dollar of the company's trailing earnings. QLGN's current PE ratio of N/A is calculated by dividing its stock price of $3.21 by its TTM earnings per share of -$2.65.
Frequently asked questions
QLGN pe ratio · 6 questionsQLGN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.21 and TTM EPS of -$2.65. Data sourced from Financial Modeling Prep via QLGN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Qualigen Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08